Advertisement

Topics

Topas Therapeutics, Eli Lilly Sign Multi-Year Research and Option Agreement Focused on Immune Tolerance

16:00 EDT 24 Aug 2017 | Drug Discovery Development

Financial details of the collaboration are not being disclosed.
Contributed Author: 
Topas Therapeutics
Topics: 

Original Article: Topas Therapeutics, Eli Lilly Sign Multi-Year Research and Option Agreement Focused on Immune Tolerance

NEXT ARTICLE

More From BioPortfolio on "Topas Therapeutics, Eli Lilly Sign Multi-Year Research and Option Agreement Focused on Immune Tolerance"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...